Allurion Technologies (NYSE:ALUR) Earns Buy Rating from Roth Mkm

Roth Mkm restated their buy rating on shares of Allurion Technologies (NYSE:ALUR) in a report released on Friday morning,Benzinga reports. Roth Mkm currently has a $16.00 target price on the stock.

Separately, Chardan Capital reiterated a “neutral” rating and issued a $2.50 target price on shares of Allurion Technologies in a research report on Friday.

Allurion Technologies Price Performance

NYSE ALUR opened at $3.60 on Friday. The firm has a market capitalization of $17.24 million, a price-to-earnings ratio of -0.30 and a beta of -0.59. The company has a 50 day simple moving average of $4.00 and a 200-day simple moving average of $10.19. Allurion Technologies has a 52-week low of $2.15 and a 52-week high of $98.75.

Hedge Funds Weigh In On Allurion Technologies

An institutional investor recently raised its position in Allurion Technologies stock. Geode Capital Management LLC lifted its holdings in shares of Allurion Technologies Inc. (NYSE:ALUR) by 40.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 516,330 shares of the company’s stock after purchasing an additional 149,484 shares during the quarter. Geode Capital Management LLC owned approximately 0.80% of Allurion Technologies worth $317,000 as of its most recent SEC filing. 21.39% of the stock is owned by institutional investors and hedge funds.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.